Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05767684
Status:
RECRUITING
Last Update Posted:
2023-08-25
First Post:
2023-03-02
Brief Title:
Neoantigen Derived DCs as Cancer Treatment
Sponsor:
National Health Research Institutes Taiwan
Organization:
National Health Research Institutes Taiwan
Study Overview
Official Title:
Personalized Neoantigen Derived Dendritic Cell-Based Immunotherapy as Cancer Treatment
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tumor lysate or carcinoembryonic antigen CEA derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit One possible reason is the lack of effective antigen and the immunosuppressive microenvironment Now we are exploring another new strategy prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGFanti-PD-1
Detailed Description:
The human immune system can recognize and destroy cancer cells but cancer cells are capable of escaping from immune system by different ways including the PD-1PDL-1 axis and the VEGF signaling pathway The PD-1PD-L1 axis represents an adaptive immune resistance mechanism exerted by tumor cells Previous study also revealed VEGF-A could induce tumor-associated macrophages Treg cells and myeloid-derived suppressor cells creating an immunosuppressive microenvironment that prevent the maturation of dendritic cells DCs and inhibit the activation of NK cells and T cells Our research group already completed some early phase clinical trials of DCs-based therapy which illustrated tumor lysate or carcinoembryonic antigen CEA derived DCs-based therapy is feasible and safe in patients with advanced colorectal cancer and lung cancer respectively However although DCs-based therapy elicited remarkable T-cell responses but mostly did not really transfer into significant clinical benefit in previous study One possible reason is the lack of effective antigen and the immunosuppressive microenvironment Now we are exploring another new strategy prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGFanti-PD-1
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None